Fondazione FORT

La Fondazione Ricerca Traslazionale (FoRT), si propone di svolgere attività scientifica e di ricerca nel settore biomedico con particolare, ma non esclusivo, interesse alla ricerca traslazionale applicata in campo oncologico, pre-clinico e clinico.

"PF‐06463922 for crizotinib pretreated ROS1 positive nonsmall‐cell lung cancer: a phase II Trial (PFROST)"

"Crizotinib in pretreated metastatic non-small-cell lung cancer with MET amplification or MET exon 14 mutation or ROS1 translocation (METROS)"

"(Squamous Immunotherapy Nivolumab-Ipilimumab Trial): An open-label, randomized, parallel, non comparative phase II trial of nivolumab plus ipilimumab versus platinum-based chemotherapy plus nivolumab in chemonaive metastatic or recurrent Squamous-Cell Lung Cancer (SqLC) "

"Serum cytokine levels as predictors of the efficacy of aflibercept in combination with FOLFIRI in metastatic Colo-Rectal Cancer patients (mCRC)"

"Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation"

"Crizotinib in ALK rearranged non-small-cell lung cancer: a retrospective study"

"Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-small-cell lung cancer patients"

"Phase II trial evaluating the efficacy of durvalumab (MEDI4736) as second-line therapy in Non-Small-Cell Lung Cancer patients receiving concomitant steroids"

"Database patologie polmonari"

IMMUNOBLOOD

"Prospective study evaluating the development of anti-checkpoint inhibitor antibodies in patients treated with immunotherapy"

"A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR mutations"

"NTRK 1,2,3 rearrangements in patients with solid tumors"

Combi-TED

"A multicenter, Phase II, open label, randomized trial evaluating the efficacy of Tedopi plus docetaxel or Tedopi plus nivolumab as second-line therapy in metastatic non-small-cell lung cancer progressing after first-line chemo-immunotherapy (Combi-TED)"

"Phase II, two-cohorts, randomized trial comparing standard of care versus immune-based combination in relapsed stage III non-small-cell lung cancer (NSCLC) pretreated with chemoradiotherapy and durvalumab"

CHIUDI X
 
CHIUDI X
 
CHIUDI X